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Abstract
Normal wound healing is a dynamic and complex multiple phase process involving coordinated interactions
between growth factors, cytokines, chemokines, and various cells. Any failure in these phases may lead wounds to
become chronic and have abnormal scar formation. Chronic wounds affect patients’ quality of life, since they
require repetitive treatments and incur considerable medical costs. Thus, much effort has been focused on
developing novel therapeutic approaches for wound treatment. Stem-cell-based therapeutic strategies have been
proposed to treat these wounds. They have shown considerable potential for improving the rate and quality of
wound healing and regenerating the skin. However, there are many challenges for using stem cells in skin
regeneration. In this review, we present some sets of the data published on using embryonic stem cells, induced
pluripotent stem cells, and adult stem cells in healing wounds. Additionally, we will discuss the different angles
whereby these cells can contribute to their unique features and show the current drawbacks.
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Background
Skin ulcers develop in the case of tissue disintegration
and are caused by many different factors, from long-
term pressure or lack of circulation and trauma [1]. The
process healing of skin ulcers is composed of the co-
ordination of three overlapping but distinct phases. This
includes inflammation, proliferation and remodeling.
The wound-healing process is highly regulated by secre-
tion of various growth factors, cytokines, and chemokines
[2]. Disruption of the cellular and molecular signals of
these stages can lead to chronic wound formation [3].
Common wound care involves selecting appropriate
dressings to maintain a favorable wound-healing environ-
ment, control infection control, debride the tissue, and
address the underlying causes such as ischemia and dia-
betes. Nevertheless, the efficacy of the current treatment
modalities is a limited success and incurs considerable
costs. The approach of regenerative medicine has emerged
as an alternative to provide additional therapeutic options
to potentially improve wound healing and restore normal
skin architecture [4–6]. Stem cell-based therapy has
become a promising new approach in the field of re-
generative medicine. The considerable interest in the bio-
logy of stem cells is concerned with their capacity for
self-renew and differentiate multiple cell types and is
crucial for physiologic tissue renewal and regeneration
after injury [7]. Researchers would anticipate achieving
acceleration in healing, earlier wound closure, prevention
of wound contracture and scar formation, and ideally
regeneration of the skin using stem cell administration.
However, determining the optimum source, a method of
processing and administration from the clinical stand-
point, as well as defining the roles of stem cells in the real
clinical situation, is still the remaining challenge for using
stem cells for their regenerative wound healing [8]. In
this review, we will discuss the use of stem cells in
skin regeneration.
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Anatomy of skin
The skin is considered one of the most vital organs in
the body due to its important functions as a protective
barrier against various external agents and a temperature
regulator [9]. It is made up of three layers: epidermis,
dermis, and hypodermis (subcutaneous layer) [10]. The
epidermis forming the outermost layer provides a water-
proof barrier playing a crucial role in controlling the
moisture into the body [11]. Keratinocytes are the most
abundant cells present in the epidermis (approximately
90%), whereas the remaining population of epidermal
cells was occupied by melanocytes, Langerhans cells,
and Merkel cells [12]. The epidermis is generally
composed of several layers according to keratinocytes
morphology. In fact, keratinocytes are formed by
division germ cells (basal cells) at the basal cell layer
while migrating through a granular layer to the upper
epidermal layers to form a dead cell on the surface of
the skin [13]. Dermis accounts for approximately 90% of
the weight of the skin and forms the foundation of this
organ system [14]. The dermis represents the inner layer
of the skin between the epidermis and the hypodermis
[15]. The dermis is a connective tissue consisted of
extracellular matrix (ECM), vascular endothelial cells,
and fibroblasts, along with adipose glands, sweat glands,
hair follicles, blood vessels, and nerve endings. Fibro-
blasts are the main dermal cell population releasing
collagen and elastin, resulting in mechanical strength
and elasticity of the skin [16]. The hypodermis is the
deepest layer of the skin consisting of loose connective
tissue, and cells storing fat (half of the body fats stored
in this place), blood vessels, and nerves. The tissue is
especially rich in proteoglycan and glycosaminoglycans
absorbing fluid into the tissue (holds the water inside)
and giving it mucous-like properties [17].
Wounds
The wound is described as injury and any disorder in
the normal structure of the skin, which can cause loss of
conjunction in the body tissue [18]. One of the most
substantial proceedings in healing each wound should
identify the cause of the wound. As a result, the wounds
are defined as open and closed wounds based on their
nature [19]. Time is a significant parameter in wound
healing and repair. Accordingly, wounds are clinically
divided into two acute and chronic groups [19]. Wounds
destroying the integrity of soft tissue and closure spon-
taneously by following timely and orderly progression
(between 4 and 6 weeks) are assorted as acute wounds
[20]. In addition, acute wounds can be caused by various
mechanisms or environmental exposure such as extreme
temperature changes, contact with chemicals, and
radiation, resulting in the entrance of the organism into
the body and infection. They can be graded according to
their size, depth, and location [21]. Chronic wounds can
be created for many reasons, including infection, physical
agents, inflammation, and tumors. Unlike acute wounds,
healing of chronic wounds is delayed (more than 12
weeks) due to prolonged pathological inflammation, while
the process of treatment is similar in both types [22].
The processes and characteristics of dermal
wound repair
Wound repair is a normal and complex biological
process in the human body occurring in all tissues and
organs [23]. It depends on the type of injury, the under-
lying disease, systemic mediators, and local wound
factors [24]. Dermal wound repair is a highly dynamic
process involving interaction between epidermal and
dermal cells, controlled angiogenesis, the extracellular
matrix, and plasma-derived proteins (coordinated by
cytokines and growth factors) [25]. The many biological
mechanisms overlapping during the progression of the
skin wound repair reaction can describe the loss of
consensus on the number of phases involved in this
reaction. However, all researchers maintain that these
phases are interrelated, and suggest that the wound
repair process is a continuum [26]. The immediate aim
of repair is to achieve tissue homeostasis and integrity in
order to accomplish this aim as the repair process
consisting of three phases: inflammation, proliferation,
and tissue remodeling [27]. These phases and their
physiological functions occur in a regulated and precise
manner since discontinuities, aberrancies, or lengthening
in the process can lead to delayed wound repair or a
non-repair chronic wound [28].
Inflammation
Inflammation occurs immediately after tissue damage,
and the key aim of this phase is to prevent infection
[20]. Since the mechanical barrier as the frontline
against exceeding microorganisms is no longer intact.
The inflammatory phase is separated vascular response
(hemostasis) and cellular response (inflammation) [29].
The vascular response consists of platelet activation
leading to the formation of a fibrin clot and repair of the
vascular system of the injured tissue. The fibrin clot is
made of platelets, collagen, fibronectin, and thrombin.
The fibrin clot provides a scaffold for using monocytes,
neutrophils, endothelial cells, and fibroblasts [30]. The
inflammatory response begins with the release of
cytokines such as transforming growth factor (TGF-β),
platelet-derived growth factor (PDGF), epidermal growth
factor (EGF), fibroblast growth factor (FGF), and inter-
leukin 8 (IL8/CXCL-8) from the fibrin clot and directly
from the damaged tissue [29]. These work as strong
chemotactic signals to recruit neutrophils to the wound.
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Neutrophils have various mechanisms for removing bac-
teria, foreign particles, and damaged tissue. They have the
phagocytotic activity for ingesting and destroying foreign
particles. They can also degranulate and release various
toxic substances (i.e., eicosanoids, cationic peptides, and
proteinases, i.e., elastase, proteinase 3, cathepsin G, and an
urokinase-type plasminogen activator), which will remove
bacteria and dead host tissue. Oxygen-derived free radical
species have bactericidal properties produced as a
by-product of neutrophil activity [20]. Approximately 3
days after injury, neutrophils decrease in number and are
replaced with macrophages. They have many tasks such as
promotion and resolution of inflammation, host defense,
removal of apoptotic cells, and support of cell proli-
feration and tissue restoration [2].
Proliferation
The proliferative stage of healing arises approximately
2–10 days after wounding and is determined through
interaction between different cell types. Initially, ke-
ratinocytes are called to the injured dermis and then
the angiogenesis occurs. During angiogenesis, capillary
sprouts accompanied by fibroblasts and macrophages
replace the fibrin clot, which is termed as granulation
tissue. Various factors are involved in this process among
which vascular endothelial growth factor (VEGF) and FGF
play a focal role in the regulation [20]. Furthermore,
angiogenesis is triggered by stimulation of the bone mar-
row and endothelial progenitors at normal concentrations
of oxygen. In the final stage, fibroblasts derived around a
wound or bone marrow motivated through macrophages
are transformed into myofibroblasts. Myofibroblasts are
identified as contractile cells and play a remarkable role in
the closure of the wound [31]. Both fibroblasts and
myoblasts synthesize and deposit ECM proteins, predo-
minantly in the form of collagen that eventually forms a
scar [32]. It is crucial to maintain a balance between ECM
protein deposition and degradation, since the disruption
of this process causes abnormalities in scarring [33].
Remodeling
The final phase of healing consists of remodeling,
which begins 2–3 weeks after injury and continue up to
2 years or more [30]. The main goal of the remodeling
stage is to extend new epithelium and apoptosis of un-
needed blood vessels, fibroblasts, and inflammatory
cells, resulting in maturation of scar [2]. During this
stage, the composition of matrix alters, and type III
collagen is eradicated and replaced with type I collagen,
which is performed by matrix metalloproteinase (MMP)
produced by fibroblasts, macrophages, and endothelial
cells to strengthen the scar [34].
Scarless healing of fetal wounds
Fetal wound scarless healing is known as an ideal
method of healing. This method is completed by some
combined actions within cells such as adhesion mo-
lecules, cytokines under the precise control of genes,
and the ECM [35]. ECM synthesis and remodeling are
essential for wound healing; recent studies have focused
on the differences between fetal and adult fibroblasts
and have revealed that in collagen gels in compression
with adult fibroblasts, fetal fibroblasts have a greater
migratory capacity, more hyaluronate receptors, and
different growth factor profiles [36]. Studies into dermal
matrices containing fetal and adult fibroblasts have indi-
cated that dermal matrices containing fetal fibroblasts
could promote scarless repair. A number of upregulated
anti-fibrotic genes and downregulated fibrotic genes
have been detected in the fetal dermal matrix [37]. The
results obtained by Hu et al. revealed that in keratino-
cytes and fibroblasts between scarless and scarring
wound, 546 genes had differential expression. They also
identified more than 60 differential pathway regulations
in scarless and scarring skin cells in fetal murine [38].
Owing to high expansion capacity under simple cul-
ture conditions, engineering of fetal tissue has high
potential for the treatment of human skin wounds
[39]. FcgammaRIII-X protein containing 249 amino
acid that is beneficial for embryonic scar-free healing
has been known as a transcript in embryonic cells with
a positive regulatory role in wound healing [40]. Research
studies have indicated fetal wound healing have a different
inflammatory response than adult wound healing [41].
The levels of immune cells, i.e., macrophages, are reduced
and less activated in fetal wound healing compared to
immune cells in adult wound healing. Furthermore, in
fetal wound healing, the presence of inflammatory cells is
short-lived compared to adult wound healing [42], indi-
cating that the reduced number of inflammatory cells
means lower expression levels of some growth factors and
cytokines over a shorter time [43, 44]. There are some
fetal regeneration differences compared to scar-forming
healing, which may result in new therapeutic targets to
prevent or at least reduce adult healing scarring [45].
Dermal and nature substitute
Dermal substitutes play a crucial role in reducing scar
formation in skin reconstruction, inhibiting excessive
proliferation and improving softness and contracture as
well as improving mechanical wear resistance. By placing
these substitutes in the wound bed, it is proposed that
the cells and ECM can grow and develop to complete
the dermal regeneration [46]. The materials should be
appropriate to supply the cells’ nutrition and enable
growth and metabolism [47]. There are various materials
for dermal substitutes divided into natural biological
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materials and synthetic polymer materials. Four best
types of natural materials are collagen, chitosan, hyalu-
ronic acid, and carboxymethyl chitosan. Collagen is
available in the human and animal connective tissues. It
has a high degree of cell adhesion, the ability to support
cell migration, and good biodegradability. Chitosan is
another natural polymer most widely used next to colla-
gen in wound healing owing to its many advantages such
as biocompatibility, biodegradability, hemostatic activity,
and antibacterial properties [48, 49]. The particular flexi-
bility and elasticity of chitosan can significantly reduce
scar development when used for burn wound healing
[50]. Chitosan can stimulate collagen synthesis and FGF
due to the chitosan electrostatic function, which can
enhance the wound-healing rate [51, 52]. The films, gels,
or sponges of chitosan have recently been investigated
for use in full-thickness burn wounds [53]. However,
chitosan has rapid biodegradability that is often formed
in wound healing [54]. In addition, an important water-
soluble chitosan known as carboxymethyl chitosan is
derivative having better water-solubility and biocompati-
bility than chitosan [53]. Hyaluronic acid by chemical
crosslinking and surface modification can improve the
mechanical properties and cell affinity of scaffolds [55].
According to various products developed in the last 30
years, dermal substitutes can be categories in natural
dermal substitutes and artificial dermal substitutes,
which some of them have been used for clinical treat-
ment [56]. Natural dermal substitutes replicate the colla-
gen three-dimensional structure and have excellent
biocompatibility. In addition, their tissue composition is
the closest one to autologous skin [57]. In summary, the
success of using natural biodegradable cell matrices has
been encouraging and continues to facilitate broader use
in the future. However, numerous problems such as low
mechanical strength, shrinkage/contraction, difficulty in
handling, and risks of immunological rejection occurring
with natural polymers have been caused [58].
Factors related to dermal regeneration
To develop better substitutional medical approaches to
improvement of injured skin tissues, regenerative medi-
cine applications have been widely investigated. Regenera-
tive therapies consist of different technological approaches
such as gene targeting, stem cell treatment, soluble mole-
cules, cell reprogramming, and tissue engineering [59]. In
particular, a basic principle for these applications is using
engineering techniques to facilitate a natural wound-heal-
ing cascade by providing proper physicochemical and bio-
chemical factors [60]. A number of bioactive factors,
including growth factors and cytokines, are involved in
various tissue repair stages and are necessary to promote
dermal regeneration. Cytokines are extracellular signaling
proteins secreted by many cell types affecting the activity
of other cells, including immune cells. They include inter-
leukins, lymphokines, interferons, and tumor necrosis
factor [61]. The study of cytokines in wound healing is
challenging, since examination of isolated cytokine
responses in the human body usually represents an over-
simplification of the phenomena. Additionally, modifying
the healing process by regulating the cytokine milieu is a
considerable challenge, since cytokine responses depend
on time and concentration in the wound bed [62]. Growth
factors are signaling proteins that release at the wound site
and are required for communication between various cells
such as smooth muscle cells, fibroblasts, myofibroblast,
keratinocytes, endothelial cells, and immune cells [63].
They can induce angiogenesis supplying oxygen and nutri-
ents to cells transplanted for organ substitution to main-
tain their biological functions [64]. Different studies on
human patients have confirmed that growth factors such
as PDGF are involved in enhancing the wound-healing
rate in acute wounds and even provide complete healing
in chronic wounds [59]. Therefore, the development of
regenerative medicine applications with the aid of
exogenous growth factors could be an alternative
clinical solution for skin regeneration.
Transforming growth factor beta (TGFβ)
The TGF-β superfamily consists of 33 members. In
mammals, mainly TGF-β1, β2 and β3 isoforms are
found, but TGF-β1 predominates in cutaneous wound
healing. They are produced by macrophages, kera-
tinocytes, fibroblasts, and platelets [59]. These three
isoforms share 60–80% homology and are encoded by
different genes. All three isoforms are believed to bind
and signal through the two TGF-β receptors (TβRI and
TβRII). TβRI activates the SMAD intracellular signaling
pathway through Phosphorylation of Smad2 and Smad3
binding to Smad4, translocates into the nucleus, and
activates transcription of target genes [65]. TGF-β can
also activate a number of nonSmad signaling pathways,
including ras/MEK/ERK, which requires the heparan
sulfate-containing proteoglycan (HSPG) syndecan 4;
p38, which requires the HSPG β-glycan; and c-Jun
N-terminal kinase (JNK), which requires focal adhesion
kinase and TGF-β-activated kinase (TAK) [66]. Much of
the current knowledge on TGF-β action in wound healing
has been obtained from animal studies using incisional
and/or excisional wound models [67]. Preclinical studies
indicated a significant reduction in scarring and consi-
derably improved dermal architecture after intradermal
injection of avotermin (TGF-β3) in adult rats [59]. In adult
mammals, high levels of TGFβ1 and TGFβ2 and low levels
of TGFβ3 facilitate scar-forming healing, while in fetal
mammals, high levels of TGFβ3 and low levels of TGFβ1
and TGFβ2 favor scar-free healing [67]. Other evidence
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support the involvement of TGFβ in regeneration, includ-
ing using the potent small molecule inhibitor [67, 68]
and experiments with zebrafish [69]. Overall, these experi-
mental observations support the role of TGFβ signaling in
wound healing, including both non-specific scar formation
and tissue-specific regeneration [70].
Vascular endothelial growth factor (VEGF)
The VEGF is the most important signaling growth factor
in angiogenesis and vasculogenesis. VEGF is involved in
wound healing and is secreted by platelets, macrophages,
fibroblasts, and keratinocytes [59]. The VEGF family
consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D, and
VEGF-E and placental growth factor. VEGF-A is one of
the most potent proangiogenic molecules in the skin. It
has been widely investigated as an exogenous cargo
growth factor for skin tissue regeneration [60]. VEGF-A
is a 45 kDa heterodimeric heparin-binding protein. Mul-
tiple isoforms of VEGF-A can be generated through al-
ternative splicing. VEGF-A interacts with multiple
receptors, including VEGF receptor-1 (VEGFR-1) and
VEGF receptor-2 (VEGFR-2). These are tyrosine kinase
receptors that differ in their ligand binding properties
and tyrosine kinase activity. Although VEGF-A binds
VEGFR1 with a higher affinity than VEGFR-2, VEGFR-2
exhibits stronger inherent tyrosine kinase activity [71].
VEGFR-2 is believed to be more important than the two
receptors in terms of controlling endothelial cell func-
tion and regulating angiogenesis based on its superior
ability to stimulate downstream signaling cascades. On
ligand binding, VEGFR-2 dimerizes, resulting in kinase
activation and autophosphorylation of tyrosine residues.
Phosphorylation of these residues leads to activation of
protein kinase B (inhibits apoptosis), the mitogen-acti-
vated protein kinase (MAPK) pathway (induces prolifer-
ation), Src kinase, focal adhesion kinase, and p38 MAPK
(leads to cell migration) [72]. It has been demonstrated
that VEGF acts as an important regulator of angiogenesis
(physiological and pathological) by inducing proliferation
of fibroblasts and endothelial cells as well as by promoting
neovascularization, re-epithelialization, and collagen de-
position [73]. Artificial three-dimensional scaffolds have
been used as efficient dermal regeneration templates f to
treat skin defects created by burns, trauma, and chronic
diseases in regenerative medicine. Inadequate angiogen-
esis is often caused during application of such scaffolds.
Tan et al. used collagen scaffolds with VEGF in a dia-
betic rat wound model and found that the treatment re-
sulted in an enhanced healing rate, improved
vascularization, and increased level of VEGF in the
granulation tissue [74]. Using plasmid DNA encoding
activated VEGF-165 in collagen-chitosan dermal equi-
valents to treat the full-thickness burns could result in a
significantly higher number of newly formed and
mature blood vessels, enabling fast regeneration of
the dermis [75].
Platelet-derived growth factor (PDGF)
The PDGF is an important biochemical mediator of
wound healing and promotes cellular reactions through-
out all phases of the wound-healing process. PDGF is
known to improve dermal regeneration, promote local
protein and collagen synthesis, and cause angiogenesis
[76]. PDGF comprises a family of homodimeric or
heterodimeric growth factors: PDGF-AA, PDGF-AB,
PDGF-BB, PDGF-CC, and PDGF-DD. It is mainly se-
creted from the α-granules of the platelet, but it is
also released by different cells such as keratinocytes,
macrophages, fibroblasts, and endothelial cells [60].
There are two PDGF receptors (PDGFR), PDGFR-alpha
(PDGFRA) and PDGFR-beta (PDGFRB), engaging several
well-characterized signaling pathways such as Ras-MAPK,
PI3K, and PLC- γ, which are known to be involved in mul-
tiple cellular and developmental responses [77]. Dermal
fibroblasts are one of the major target cells of PDGF in
initiation and propagation of skin tissue repair. They se-
crete PDGF-BB and express PDGFRB receptor. PDGF-BB
stimulates Wnt2 and Wnt4 mRNA expression. In terms
of its relevance to wound healing and skin tissue regene-
ration, PDGF-BB exhibits chemotactic, mitogenic, angio-
genic, and stimulatory effects, leading to modification of
the extracellular matrix by stimulating collagen, colla-
genase, and glycosaminoglycan synthesis [78]. PDGFRB
targeted deletion studies into dermal fibroblasts have
demonstrated its role in transducing wound-healing sig-
nals accounting for an 85% reduction of granulation tissue
mass [79]. Therefore, wound treatment using exogenous
PDGF has been studied by developing a cellular collagen-
chitosan temporary matrix of a wound site for in vivo
dermal regeneration. This study suggested that PDGF
supplementation could have altering effects on oxidative
events depending on the duration of the wound-healing
process [80]. In another study, a combination of
AMD3100 (which mobilizes marrow-derived progenitor
cell) and PDGF-BB therapy has been synergistically shown
to improve progenitor mobilization and trafficking,
resulting in significantly improved diabetic wound
closure and neovascularization [81].
Fibroblast growth factor (FGF)
The FGFs include a family of polypeptides growth factors
which have been demonstrated to have considerable ca-
pability in tissue repair and regeneration. It was originally
identified to induce proliferation and differentiation in
various types of the cell [82]. The interaction of FGFs with
their receptor tyrosine kinases (FGFRs) in the presence of
heparin/heparan sulfate (HS) proteoglycans (HSPG) as a
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cofactor results in activation of FGFRs by phosphorylation
of tyrosine residues [83]. Activated FGFRs lead to trig-
gering a number of signaling pathways such as the
RAS/MAP kinase pathway, PI3 kinase/AKT pathway,
and PLCγ pathway, resulting in specific cellular responses
[84]. Regeneration is controlled by a different type of
growth factors among which FGFs are the key players in
tissue regeneration, including the neural, liver, bone, skin,
intestine, cardiac, and muscle [85]. According to the
amino acid sequence, the FGF family is divided into seven
subfamilies [86]. However, FGF2 (basic FGF) is indicated
to be widely applied for scarless wound healing and skin
wound regenerative therapy [87]. It has been reported that
the sustained release of basic FGF from a chitosan film
as a delivery vehicle could accelerate wound healing in
full-thickness skin wounds made on the backs of
genetically diabetic mice and promote proliferation of
fibroblasts and granulation tissue formation [52]. In
another study, incorporation of bFGF with gelatin
microspheres significantly accelerated dermal tissue
regeneration [88]. Furthermore, studies have identified
that FGFs are key regulators of keratinocyte migration
in wounded skin, as the loss of FGFR1 and FGFR2 in
keratinocytes results in a wound-healing defect [89].
Hepatocyte growth factor (HGF)
The HGF was originally discovered as a mitogen of
hepatocytes to be produced by stromal cells. HGF
stimulates many properties of the epithelial cell, including
proliferation, motility, morphogenesis, and angiogenesis
via tyrosine phosphorylation of its receptor, tyrosine-pro-
tein kinase Met (c-Met) [90]. The mature form of HGF is
composed of α/β heterodimers linked by a disulfide bond.
The α-chain contains an N-terminal hairpin domain and
first Kringle domain and exhibits a high-affinity binding
site for Met, and the β-chain has a serine protease-like
structure; although the α-chain is required for Met
binding, it is not able to activate Met and the β-chain
induces the activation of Met and biological responses
[91]. The binding of HGF to its receptor, c-Met, results
in structural changes in c-Met and phosphorylation of
protein tyrosine kinase (PTK) domain. Subsequently,
two other phosphotyrosines in the carboxy-terminal
multifunctional docking domain recruit intracellular
signaling molecules Grb2 (growth factor-receptor-
bound protein 2), Gab1 (Grb2-associated binder 1), phos-
phoinositol 3-kinase (PI3K), MAPK, PLCγ (phospholipase
Cγ) and Shp2 (SH2-domain-containing protein tyrosine
phosphatase 2), signal transducer and activator of tran-
scription factor (STAT) pathway [92, 93]. Therefore,
c-Met and its related signaling pathways play a crucial role
in the diverse process, including embryogenesis, wound
healing, organ regeneration, and mature tissue survival
[94]. It promotes mitogenic, morphogenic, and mitogenic
activity in various cell types. HGF/Met contributes to
immune regulation by modulation of DC migration and
activation of monocytes and macrophages [95, 96]. HGF is
a cytokine known to play multiple roles during the various
stages of wound healing and accelerates wound healing by
promoting the dedifferentiation of epidermal cells
through 1-integrin/ILK pathway [97]. According to
this study, HGF increased the expressions of the cell adhe-
sion molecules 1-integrin and the cytoskeleton remod-
eling protein integrin-linked kinase (ILK) in epidermal
cells in vivo and in vitro. Baek et al. [98] demonstrated
that Met signaling in skin-resident DCs was essential for
their emigration toward draining lymph nodes upon
inflammation-induced activation. These findings were
supported using a conditional Met-deficient mouse
model where activated skin resident DCs failed to
migrate toward the skin-draining lymph nodes despite
an activated phenotype.
Epidermal growth factor (EGF)
The EGF is primarily secreted by platelets, macrophages,
fibroblasts, and keratinocyte and is present during
dermal wound healing and facilitates skin regeneration.
The binding of EGF to EGFR activates EFGR through
ligand-induced dimerization, leading to a downstream
signaling cascade, including Ras/MAPK, PLCγ/PKC,
PI3K/Akt, and STAT [99, 100]. These signaling path-
ways are classified into four different categories:
migration, proliferation, cytoprotection, and EMT among
which migration and proliferation pathways have been
required for wound healing [101]. EGF is influenced by
different components of the keratinocyte migration
machinery and induces contraction of keratinocytes,
which are critical to wound re-epithelialization [102].
Despite extensive progress in the exogenous EGF in
the treatment of acute wounds, its efficacy in chronic
wound therapy is limited owing to their short half-life
in vivo and poor transdermal permeability [103]. To
overcome these restrictions, EGF was conjugated to an
efficient delivery system to extend the residence time of
EGF in the wound area and significantly regenerated
skin tissue [104, 105].
Development and application of stem cell
technologies
The main clinical focus of stem cell application in wound
care is to target improved quality of wound healing. The
medical practitioner would anticipate achieving acce-
leration in healing, prevention of wound contracture and
scar formation, earlier wound closure, and ideally re-
generation of the skin and its appendages using stem
cells [8]. Stem cells, defined based on the findings
obtained by McCulloch and Till [7], are characterized by
their capacity for self-renewal, asymmetric replication, and
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differentiation to other cells building different tissues and
organs. Stem cells replenish lost cells throughout an or-
ganism’s lifespan. They have the capacity for unlimited
replication providing a population of “sister” SCs. These
cells are responsible for self-renewal and differentiate
tissue-specific cells. This process maintains the constant
number of aging somatic cells, which have become apop-
totic. Their therapeutic potential is largely due to their
capability to secrete pro-regenerative cytokines, causing
them to be an attractive choice for the treatment of
chronic wounds [6]. Among the main sources of cells that
might be used for wound healing and regeneration of
injured skin are embryonic stem cells (ESCs), induced
pluripotent stem cells (iPS), and adult stem cells [106].
However, the remaining challenge of stem cell application
for skin regeneration is still to describe the optimum
source and the method of processing and administration
from a clinical standpoint and to define the roles of stem
cells in the real clinical situation [107]. Table 1 shows stem
cells used for wound therapeutic.
Embryonic stem cells (ESCs)
The ESCs were first established from the inner cell mass
(ICM) of mouse blastocysts in 1981, and the term
“embryonic stem (ES) cell” was coined [108]. ES cells are
pluripotent stem cells derived from the inner cell mass
of the preimplantation blastocyst (35-day-old embryo)
and obtained from mice, humans, and nonhuman
primates. ES cells have the ability to differentiate cell
types, including neural cells, blood cells, adipocytes,
chondrocytes, muscle cells, and skin cells [109]. In an
attempt to utilize the remarkable regenerative potential of
ESCs for cutaneous repair, Guenou et al. showed that hu-
man embryonic stem cells growing in induction medium
containing BMP4 (bone morphogenetic protein-4) and as-
corbic acid could differentiate between basal keratino-
cytes, which were subsequently used to reconstitute the
epidermis composed of multiple layers of differentiated
cells. These tissues were also successfully transplanted into
nude mice to facilitate wound healing [110]. In another re-
port, Shroff et al. evaluated the effect of human embryonic
stem cell (hESC) therapy in six patients with non-healing
wounds. It showed that the wounds of all the patients
healed after receiving hESC therapy. Reduction in the size
of wounds and granulation was observed among all the
patients [110]. Despite these promising findings, the use
of embryonic stem cells has remained controversial. The
cells could be the most suitable ones over adult stem cells
for skin tissue regeneration owing to their capacity of
self-renewal and the unlimited supply of differentiated
keratinocytes or keratinocyte progenitors for treating
cutaneous injuries [111]. In addition to the widespread
clinical use of ESCs, which is currently elusive due to the
potential for immunogenicity and tumorigenicity, another
major limitation of using ESC-derived cells for regene-
rative wound healing is ethical controversy and substantial
legal restrictions [7].
Induced pluripotent stem cells (iPS cells)
The iPS cells are the newest class of pluripotent stem
cells, which potentially combines the advantages of
MSCs and ESCs, ushering in a new era of regenerative
medicine [6]. In 2006, Yamanaka et al. [112] at Kyoto
University in Japan observed that the introduction of
four genes (Oct-3/4, Sox2, c- Myc, and KLF4) into cells
from the mouse tail could reprogram the cell back to an
embryonic state. In 2007, iPS cells were produced from
human cells [113]. These induced pluripotent stem cells
were shown to be remarkably similar to ESCs in mor-
phology, proliferation potential, gene expression pattern,
pluripotency, and telomerase activity. Like ESCs, iPSCs
can differentiate between all types of cells from the skin
to nerve and muscle [7]. This revolutionary technology
allows for generation of autologous pluripotent stem cell
populations, thereby circumventing the major limitations
of ESC, including ethical concerns and potential for
immunological rejection [113]. Taking advantage of these
characteristics, significant progress has been made in the
differentiation of iPSCs into skin cells—including folli-
culogenic human epithelial stem cells, fibroblasts, and
keratinocytes—to engineer skin substitutes [106].
Bilousova et al. induced iPS cells in vitro to differentiate
skin-like cell lines and to form multi-differentiated
epidermis, hair follicles, and sebaceous glands [114].
Additionally, Itoh et al. [115] generated in vitro 3-D skin
equivalents exclusively composed of human iPSC-derived
keratinocytes and fibroblasts. Two recent studies con-
ducted by Umegaki-Arao et al. [116] and Sebastiano et al.
have further proven this concept. One of the most recent
studies in this regard suggested that exosomes derived
from human-induced pluripotent stem cell-derived mes-
enchymal stem cells (hiPSC-MSCs) facilitated cutaneous
wound healing in rats by promoting collagen synthesis
and angiogenesis [117]. However, despite experimental
evidence supporting the therapeutic benefits of iPSCs,
there are still numerous issues such as associated cancer
risk development through using retroviral vectors, epi-
genetic memory retained from parent cells, genetic
instability, inefficient cell re-programming yielding low
cell numbers with high processing costs, and potential
immunogenicity [118]. Therefore, iPSC-based therapies
for wound-healing applications require further extensive
analyses for safety and reliability of the reprogramming
technology [119].
Adult stem cell
The most stem cells used in skin regeneration and
wound healing are adult stem cells owing to containing
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Table 1 Stem cells used for in wound therapeutic
Stem cells types Delivery mode Wound
types
Correction
efficiency
Model
source
use
Treatment effect notes Reference
BM-SCs Scratch
wound assay
Wound
closure
3 days Human Stimulate fibroblasts, migration of keratinocyte and
synthesis ECM proteins
[238]
BM-SCs Tail vein
injection post-
operatively
Ischemia
flap
7 days Murine Enhance angiogenesis and vascular regeneration [141]
autologous MSC Fibrin spray
system
Cutaneous
wound
12 weeks Murine
and
human
Stimulate closure of full-thickness wounds in diabetic
mice and wound healing repair
[239]
Combination
hMSC with bFGF
Cutaneous
wound
42 days Rat Increase re-epithelialization [240]
Co-culture
dermal
fibroblasts with
BM-SCs
Scratch wound
assay
Wound
closure
3 days Murine Increase proliferation and migration of dermal fibroblasts [241]
MSCs Subjection Incision
wound
4 days Mice Enhance tissue regeneration capacity especially
in older populations
[242]
Autologous
bone marrow
Aspiration Chronic
Wound
5 weeks Human Rebuilding of dermal [138]
MSCs Closed culture
devices
Radiation
burns
5 months Human Modulation radiation inflammatory process [243]
Autologous
MSCs
Injection Diabetic
ulcer
4 weeks Human Successful healing [244]
Allogeneic
BM-SCs
Intradermal Excisional
wound
14 days Murine Accelerate wound closure, increase re-epithelialization
and angiogenesis
[245]
BM-SCs Aspiration Non-
healing
wound
5 days Human Increase synthesis of collagen [246]
MSCs Injection Cutaneous
wound
2 weeks Human Promote angiogenesis [247]
MSCs Mechanical
loading
Incision
wound
Mouse Enhancement of angiogenesis [248]
hUC-MSCs) Transplantation Burn 8 weeks Rat Decrease inflammatory cells, increase neovascularization
and enhance collagen level
[249]
ASCs Transplantation Non-
irradiated
and
irradiated
14 days Mouse Promote dermal wound healing, enhance wound
closure and collagen secretion
[250]
hESCs Grafting Burn Enhanced
wound healing
Human-
mice
hESC-derived epidermis showed a pluristratified structure,
consistent with that of mature native human skin
[251]
ESCs Directly on
a gauze
Chronic
Wounds
Accelerated
wound healing
Diabetic
mice
The beneficial effects were evident both histopathologically
and immunohistochemically
[252]
Mouse-iPSCs Grafting Inherited
skin
disorders
Enhanced
wound healing
Mouse iPSC-KC stem cells were able to regenerate the epidermis,
hair follicles, and sebaceous glands in an in vivo graft assay
[253]
hiPSC-MSCs-
Exos
Injected locally Injured
tissues
Facilitated
cutaneous
wound healing
Human-
rat
Accelerated re-epithelialization, reduced scar widths, the
promotion of collagen maturity, promoted the generation of
newly formed vessels, accelerated their maturation in
wound sites
[254]
hiPSC Grafting Skin
disease
Reconstitution
of normal skin
structures
Human-
SCID mice
Skin appendages, such as hair follicles and glands, were
not detected, and no cyst or tumor formation
[255]
hiPSCs Grafting Inherited
skin
disorder
Reconstitute
human skin
EB
patient-
SCID mice
The reconstituted skin expressed human Col17 at the
basement membrane zone, human type VII collagen and
human keratin 14 were expressed in the basal layer
[256]
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significant proliferative capacity, long-term self-renewal
potential, and having the ability to differentiate into
other lineages. They are found in various tissues, inclu-
ding the skin, heart, liver, brain, and bone marrow. Among
the different types of adult stem cell, mesenchymal stem
cells (MSCs) and adipose-derived stromal cells (ASCs)
have gained considerable attention as a suitable candidate
to enhance tissue regeneration [120].
Mesenchymal stem cells (MSCs)
The MSCs harvested from various sites (bone marrow,
adipose tissue, amniotic fluid, and dermis) are consi-
dered a source for therapeutic approaches owing to their
multilineage differentiation, high frequency, facility of
isolation and characterization, and the ability of MSCs
to migrate to injury sites in the body [121]. These cells
are involved in all three phases during the wound-heal-
ing process. They also enhance wound healing by
immune modulation, production of growth factors,
which enhance neovascularization and re-epithelialization,
stimulate angiogenesis, and accelerate wound closure
[122]. One case study has reported that increased wound
closure occurs when MSCs are administrated and accele-
rated dermal fibroblast and keratinocyte migration [123].
Furthermore, Nakagawa et al. [124] suggested that the
combination of hMSCs with bFGF in a skin defect model
improved cutaneous wound healing as the hMSCs trans-
differentiate into the epithelium. Smith et al. [125] showed
that MSCs secreted soluble factors inducing dermal fibro-
blast proliferation, migration, and chemotaxis. Endoge-
nous bone marrow-derived mesenchymal stem cells in the
dermis may provide an important early signal for dermal
fibroblast responses to cutaneous injury. Li et al. [126]
demonstrated that activated MSCs promoted wound
healing in acute incisional wounds, as reflected in
regained tensile strength.
A clinical study was performed to test a new technique
for the treatment of chronic non-healing wound (diabetic
ulcer) using autologous graft composed of autologous skin
fibroblasts on biodegradable collagen membrane (Cola-
derm) in combination with autologous MSC derived
from the patient’s bone marrow. The wound showed a
steady overall decrease in wound size and an increase
in the vascularity of the dermis and in the dermal thick-
ness of the wound bed after 29 days of combined treat-
ment [127]. The treatment of burn injuries, especially
severe ones, has always been a challenging issue, but
the use of MSCs had beneficial therapeutic effects on
burns wound healing. A case report of radiation burns
has indicated the efficiency of a new therapeutic
approach combining surgery and local cellular therapy
using autologous MSCs, which this benefit of the local
cell therapy could be linked to the “drug cell” activity of
MSC by modulating radiation inflammatory processes
[128]. During the normal wound-healing process, angio-
genesis is one of the most important stages in which
MSCs secret various pro-angiogenic factors such as VEGF
to promote endothelial cell proliferation and form new
vessels [129]. There is evidence that suggests topical
VEGF accelerates diabetic wound healing through in-
creased angiogenesis as well as mobilizing and recruit-
ing bone marrow-derived cells [73]. Han et al. [130]
compared proliferation, collagen synthesis, and growth
factor production of human BSCs as important contri-
buting factors for wound healing, to those of dermal
fibroblasts in vitro. There were no significant differences
in cell proliferation and TGF-β production. However,
BSCs produced much higher amounts of collagen, bFGF,
and VEGF. Recently, a study has observed that local trans-
plantation of MSCs improves cutaneous wound healing
via VEGF-paracrine secreted from MSCs [131]. Kasper et
al. [132] revealed that mechanical loading of MSCs
seemed to result in a paracrine stimulation of angio-
genesis, most likely by regulating a network of several
angiogenic molecules. Experimental studies established
that MSCs could orchestrate the inflammatory response
following tissue injury. Transplantation of human um-
bilical cord MSCs into cutaneous rat wounds significantly
accelerated wound healing and remarkably decreased the
quantity of infiltrated inflammatory cells and levels of
IL-1, IL-6, and TNF-a and increased levels of IL-10 and
TSG-6 in wounds. Additionally, hUC-MSCs increased the
level of VEGF in severe burn wounds and promoted
wound angiogenesis [133]. Aggarwal and Pittenger in their
study described that MSCs were capable of modulating
allogeneic immune cell responses through reducing the
secretion of TNF-α and interferon-γ (IFN-γ) [134].
Undoubtedly, many studies have outlined that mesenchy-
mal cells are considered suitable candidates for cell-based
therapeutic approaches, but in spite of developments in
MSC-based therapy, there are a number of limitations in
the utilization of MSCs. One potential limitation in the
application of MSCs for treatment is their poor viability
following implantation, curtailing a long-term safety
profile. However, some strategies have been developed to
improve the survival of the transplanted MSCs [135]. The
self-renewal capability of MSCs and their molecular
mechanism are unknown, and it is still unclear to identify
how culture expansion alters the cellular composition and
function of populations [136].
Bone marrow-derived stem cells (BM-SCs) BM-SCs
are considered the primary source of MSCs in adults
and a good candidate for the treatment of different types
of wounds [137]. Preclinical studies using autologous
BM-MSC have reported the potential therapeutic effect
of these cells in dermal rebuilding and scarring reduc-
tion in chronic wound [138]. A study of patients with
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non-healing ulcers of the lower limb found that appli-
cation of BM-MSC led to significant improvement in
pain-free walking distance and reduction in ulcer size
[139]. BM-MSCs have been confirmed to improve indi-
cators related to wound healing through increasing re-e-
pithelialization and thickness of the regenerated
epidermis [140]. Wan et al. [141] demonstrated that
transplantation of allogeneic bone marrow-derived
mesenchymal stem cells could promote the delayed
wound healing in diabetic rats. Falanga et al. [142] stated
that the cultured autologous BM-MSC delivered to wounds
using a fibrin spray system could achieve healing in murine
and human cutaneous wounds. A study on 8 patients,
whose non-healing diabetic ulcers were treated with a com-
bination of bone marrow stem cells, platelets, fibrin glue,
and collagen matrix, presented successful healing for three
patients and a significant reduction in the remaining five
patients [143]. Wu et al. discovered that BM-MSCs
enhanced wound healing in nondiabetic and diabetic
mice by promoting re-epithelialization, cell infiltration,
and angiogenesis. Moreover, a study proved that circu-
lating bone marrow-derived MSCs home to perivascu-
lar sites in critically ischemic tissue exhibited paracrine
function and augmented microhemodynamics. These
effects were mediated through arteriogenesis and angio-
genesis, which contributed to vascular regeneration [144].
Although BM-MSC is successfully implemented in clinical
treatment, other limitations in therapeutic efficacy are
challenges that need to be addressed through an extensive
investigation of BM-MSC. The risks of BM-MSC during
clinical translation are harvesting invasiveness, in vitro
culture, and further cost-time resource.
Human umbilical cord-derived mesenchymal stem
cells (UC-MSCs) UC-MSCs show promising therapeutic
effects due to immunological compatibility, long-term sur-
vival, multi-directional differentiation potential, and easy
isolation [145]. In vitro experiments have demonstrated
that treatment of diabetic wounds with hUCB-MSCs
shows higher cell proliferation and collagen synthesis
compared to fibroblasts [146]. A similar observation
reported that transplantation of UC-MSC accelerated
wound closure in diabetic mice. Although many clinical
trials have not been developed on using UC-MSCs in
wound healing, they have advantages over BM-MSCs,
including easy preparation, high number of cells from
the cord, production large yield of MSCs, and retar-
dation of senescence [147]. Despite the considerable
therapeutic potential for stem cell to treat various
diseases, there are still concerns about potentially
dangerous consequences. One challenging area concerns
the patient’s immune system. The challenges are also
unusual since they mostly pertain to embryonic stem cells,
whereas adult stem cells can alleviate immunological
challenges that tend to accompany embryonic stem cells.
Stem cells have the potential to divide many times and
differentiate many cell types, which is their considerable
promise. Paradoxically, owing to these abilities, stem cells
also have the potential to form tumors. The possibility of
transplanted stem cells differentiating into the wrong type
of tissue is yet another concern regarding therapeutic stem
cell use. Stem cell lines used for research are not always
“pure”, because their exposure to other animal cells to
maintain viability causes contamination.
Adipose-derived stem cells (ASCs)
ASCs are pluripotent cells with the ability to differenti-
ate between various cell types. These cells have advan-
tages over MSCs, including their high accessibility with
minimal invasiveness and no ethical limitations [148].
ASCs can promote wound healing and trigger neo-
vascularization through their ability to differentiate
endothelial cells and release VEGF [149]. Another study
presented that hypoxia increased the proliferation of
ASCs and enhanced the wound-healing function of
ASCs, at least partly, by upregulating the secretion of
VEGF and bFGF [150]. Kim et al. [151] investigated that
ASCs had effects on human dermal fibroblasts (HDFs)
by increasing collagen synthesis and promoting proli-
feration of HDFs, suggesting that ADSCs could be used
for the treatment of wound healing. Furthermore, it has
been illustrated that AD-MSCs possess considerable
anti-inflammatory and angiogenic potential, in which due
to these properties, they can be distinguished from dermal
fibroblasts [152]. Such advancements demonstrate that
ADSCs are extremely promising as an alternative tool for
the regenerative strategy for wound therapy.
MSCs and immune modulation
For the first time in 2002, Bartholomew et al. indicated
that MSCs had the ability to modulate immunosup-
pression. They also showed prevention of rejection in
a baboon skin allograft model in vivo and suppression of a
mixed lymphocyte response in vitro [153]. Considering
the fact that the MSCs immune response properties were
reported for the first time, subsequent studies have
demonstrated that MSCs mediate immunosuppression
in human and animal models.
Regarding the successful preliminary clinical outcomes,
the mechanisms concerned with MSC interactions with
the immune response as understood today are worth
mentioning. MSCs can interact with various immune cells
such as T cells, B cells, natural killer (NK) cells, DCs,
neutrophil, and macrophages [154]. The interaction
mechanisms were indicated to depend on cell-cell contact
working in cooperation with the secretion of soluble
immune factors in order to induce MSC-regulated
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immunosuppression [155]. Particular modulators, such
as multitude of immune-modulatory factors, growth
factors, and cytokines, balance immune profiles and
modulate inflammatory responses [156]. In other words,
soluble immune secretomes such as 3-dioxygenase (IDO),
prostaglandin E2 (PGE-2), nitric oxide (NO), and indolea-
mine 2 respond to immune cells in order to activate
immunoregulation through MSCs [157].
Intracellular secretomes, the main histocompatibility
complex (MHC) antigens, and adhesion molecules are
all necessary to induce immune suppression. In this re-
gard, the Fas ligand/Fas receptor interaction (FasL/FasR)
and T cells play a crucial role in the function of T cell
reaction [158]. Extracellular vesicles produced by MSCs
facilitate generating regulatory T cells and M2 macro-
phages while suppressing proliferation of B cells and T
cells and maturation of monocytes [159].
In addition, MSCs are able to repair damaged cells
and tissues and regulate inflammatory progress by
adhering to inflammatory sites [160]. Integration of MSC
with inflammatory actions can restrain and fortify the im-
mune response and relies on the kinds of inflammatory
secretomes, the function of immune suppressants, and the
immune system general condition [161]. As an interesting
point, when MSCs are stimulated by inflammatory cyto-
kines such as interleukin- (IL-1) and tumor necrosis factor
(TNF), they only modulate immunosuppression [162].
MSCs not only produce immune-regulatory secretors
mediating the inflammation process but also respond to
inflammatory cytokines. For instance, many chemokines
produced by MSCs, indoleamine 2,3-dioxygenase (IDO)
in humans, and nitric oxide (NO) in mice play a major
part in MSC-mediated immunomodulation [163].
Additionally, MSC secretomes such as tumor-specific
glycoprotein (TSG6) and growth factors HGF have
been effectively used for the treatment of immune diseases
[164]. In this respect, MSCs have also been employed to
effectively treat patients with severe immune disorders
such as Crohn’s disease and SLE [165].
Immune cells interact with MSCs in immunomodulation
Both in vitro and in vivo studies have indicated that MSCs
demonstrate their multipotency as an immunomodulation
mediator. MSCs significantly affect immunosuppression
through refraining immune cells in both adaptive and
innate immune systems (Fig. 1).
Innate immunity
The innate immune system plays a crucial role not only
in the elimination of pathogens targeted by an adaptive
immune response but also in the adaptive immune
reaction [166]. NK cells, DCs, and macrophages form
the innate immune system, and their interaction with
MSCs inhibits inflammatory responses and improves
regenerative processes [167].
(A) Myeloid dendritic cells (DCs) DCs modulate and
maintain immune responses through the activation of
cells in the innate immune reaction following DC matur-
ation and acceleration of antigen-specific T cell processes
[168, 169]. Recent studies have indicated that MSCs have
immunosuppressive functions on DCs through decreasing
the cell-surface expression of CD1-α, CD40, CD80, CD83,
CD86, and MHCII, and restraining DC differentiation
from monocytes [170]. DCs, after incubation with MSCs,
would lose their ability to motivate lymphocytes by acce-
lerating IL-10 release and downregulating interferon-γ
(IFN-γ) as well as TNF-α expression [171]. In this respect,
the Notch pathway relying on IFN-γ-secretase mediates
the MSC-DC interaction [172]. PGE-2 seems to regulate
the molecular mechanisms of MSCs restraining DC
maturation [173]. Furthermore, MSCs are able to damage
DCs migration through presenting antigens for activating
T cells and suppressing molecules tied to DCs [174, 175].
Fig. 1 The function of MSCs used in innate and adaptive immune systems
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By inhibiting TNF formation, MSCs can depress the DCs
proinflammatory capacity [176]. The important point is
that MSC inhibitory effects play a crucial role in relieving
a number of immune disorders, including allograft rejec-
tion [172], type 1 diabetes, and acute GVHD [177, 178].
(B) Natural killer (NK) cells Natural killer (NK) cells
have cytolytic activity and produce proinflammatory
cytokines [179]. By immunosuppressive secretors such
as PGE2, TGF-β, and sHLA-G, MSCs inhibit the effects
of NK cells, leading to reduction of IFN-γ secretion and
induction of cytotoxic effects against virus-infected cells
[180]. Suppressing the activating NK cell receptor
expression completes this inhibitory action, which is
mediated by PGE-2 and IDO [181]. In addition to these
findings, direct cell-cell contact plays a particular role in
suppressing NK cells being associated with expression of
Toll-like receptor- (TLR-)4 on MSCs [182]. By suppres-
sing the secretion of NKp30 and NKG2D, as the surface
receptors associated with NK cell activation, MSCs
improve cytotoxic movement [183]. Nevertheless, the
potent suppressive actions of MSCs appeared only at
high MSC-to-NK ratios [180]. Moreover, it has been
indicated that activated NK cells are able to dissolve MSCs
in the case existence of activating receptors on NK cells
[184]. Overall, these discoveries demonstrate that inter-
action between NK cells and MSCs is dependent on the
ratios of both cells and their microenvironment [185].
(C) Macrophages It is clearly demonstrated that macro-
phages are significant cells in the innate immune system
with high plasticity [186]. In this regard, macrophages,
according to the specific microenvironment of MSCs, may
be polarized into classically activated M1 macrophages or
alternatively activated M2 macrophages [187]. In general,
by releasing various chemokines and inflammatory cyto-
kines, M1 macrophages possess prominent antimicrobial
properties, whereas M2 macrophages are capable of allevi-
ating inflammation and expediting tissue repair through
secretion of IL-10 and trophic factors [188]. Furthermore,
the coculture of macrophages with MSCs induces produc-
tion of M2 macrophages, downregulating levels of inflam-
matory cytokines, such as IFNγ, TNF-α, IL-1β, and IL-12,
as well as upregulating the phagocytic activity and secre-
tion of IL-10 [189, 190]. Recent studies have reported that
by responding to TLR4 ligation, then inducing monocyte
emigration, MSCs accelerate monocyte chemotactic
protein-1 (MCP1) secretion [191]. In a zymosan-induced
peritonitis injury model, by secreting TNF-stimulated gene
6 (TSG6), human MSCs activate peritoneal macrophages,
regulating TLR2 nuclear factor-κB (NF-κB) signaling [192].
Furthermore, MSCs have been demonstrated to improve
immune disorders and facilitate tissue regeneration
through increasing the macrophages concentration at
injury locations [193, 194].
Adaptive immunity
The adaptive immune system has its own specific properties,
particularly immunological memory and antigen-specific
immune response. The system is composed of CD4+ T
helper and CD8+ cytotoxic T lymphocytes transmitting
an appropriate antigen-specific immune response after
antigen-presenting cells (APCs) undergoing antigen
processing and presentation [166].
(A) T cells T cells are mostly distributed in both human
and animal tissues and, once activated, can differentiate
between T helper (Th) 1, regulatory T cell (Treg) sub-
population, Th2, Th9, or Th17, according to the cytokine
microenvironment and the stimulation intensity [195,
196]. It has been indicated that MSCs tightly interact
with T cells [197]. In this regard, T cells, as a key me-
diator of the adaptive immune system, protect organisms
from infections and malignancies, as well as modulate
different autoimmune diseases [197].
Furthermore, MSCs secrete a considerable quantity of
chemokines, immunosuppressive factors, and adhesion
molecules, being responsible for effective T cell suppres-
sion, involved in T cell apoptosis, differentiation, and
proliferation [198]. For instance, MSCs are able to
repress T cell proliferation via cellular or nonspecific mito-
genic stimuli [199] and promote activated T cell apoptosis
through the Fas/Fas ligand pathway [200]. MSCs constitu-
tively secrete coinhibitory molecule HLA-G and B7-H4,
presenting an immunosuppressive action on T cell and
influencing their T cell-mediated cytotoxicity and proli-
feration [201]. Nevertheless, MSCs immunosuppressive
capacity is not activated at all times and is dependent on
the type and strength of the inflammatory stimulation
[202]. MSCs do not restrain T cell proliferation in the
presence of pathogen-associated molecules and TLRs such
as TLR4 and TLR3 damaging Notch signaling, as a conse-
quence, recovering effective T cell to respond to pathogens
[203]. Furthermore, as a specialized subset of T cells, regu-
latory T cells restrain the effects of the immune system,
resulting in sustaining homeostasis and relieving their
own antigens [204].
(B) B cells B cells are considered the second major cell
genre associated with adaptive immune responses. The
cells resist and hunt down outside pathogens through
producing specific antibodies [205, 206]. Both human
and murine MSCs are able to inhibit B cell activation
and proliferation in vitro [207]. Furthermore, MSCs also
suppress expression of chemokine receptors and diffe-
rentiation of B cells due to secretion of soluble molecules
and cell-cell contact [208]. Metalloproteinase-processed
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CC-chemokine ligand 2(CCL2) released by MSCs sup-
press activator of transcription 3 (STAT3) activity and
signal transducer, leading to downregulating Paired box 5
(PAX5), thereby inhibiting immunoglobulin synthesis [209].
A number of other signaling pathways such as extracellular
response kinase ½, p38, Akt signaling, and B lymphocyte-
induced maturation protein 1 (Blimp1) modulate B cell
activation [210]. Nevertheless, insufficient inflammatory
signal-activated MSCs in patients with SLE may support
differentiation and proliferation of antibody-releasing B
cells [211]. Overall, MSCs suppress antibody production by
B cells; this effect depends on the MSCs to B cells ratio and
the inflammatory stimulation strength [212, 213].
Soluble factors secreted by MSCs in immunomodulation
By secreting multiple soluble immune factors, MSCs
could interact with immune cells in both innate and
adaptive immune systems to induce MSC-regulated
immunosuppression [214]. During an immune response,
some soluble factors are released by MSCs, such as
growth factors, cytokines, chemokines, and hormones,
which act on immune cells and exert their functions
through suppressing immunology activity and repairing
damaged cells [215, 216] (Fig. 2). Owing to an inflamma-
tory cytokine-licensing process by MSCs, the inflamma-
tory response is essential for MSCs to exert effects on
immunomodulation. As a result, MSC immunoregu-
latory activities require inflammatory cytokines secreted
by T cells and antigen-presenting cells, including IL-1α,
interferon- (IFN-) γ, TNF-α, and IL-1β [217]. These
inflammatory cytokines can activate MSCs to secrete
immunosuppressive factors composed of TSG6, IDO,
IL-10, NO, galectins, CCL2, TGF-β, and PGE2 and then
modulating tissue homeostasis [159, 218].
Indoleamine 2,3-dioxygenase (IDO)
It has recently been reported that by suppressing various
immune cells such as T cells and NK cells, IDO mediates
immunomodulation [212, 219]. IDO can restrain the
effect and proliferation of immune cells through trans-
forming tryptophan into its metabolite kynurenine [220].
In addition, IDO secreted by MSCs is capable of suppress-
ing allogeneic T cell reactivity and promoting kidney
allograft tolerance [221]. Furthermore, IDO has been sug-
gested to be one of the immunosuppressive molecules
representative for human MSCs [212, 222].
TNF-stimulated gene 6 (TSG6)
TSG6 has anti-inflammatory effects as a multifunctional
protein [223]. Proinflammatory mediators like IL-1 and
TNF-a may stimulate TSG6 secretion [224]. It has been
reported that in a mouse model of myocardial infarction,
microembolization induces TSG6 to interact with
damaged lung. Therefore, TSG6 plays a crucial role in
enhancing cardiac function, as well as reducing in-
flammation and infarct size [225].
NO
MSCs, in the presence of proinflammatory cytokines, accel-
erate high expression of inducible NO synthase (iNOS),
stimulating the secretion of NO, and leading to inhibition
of T cell proliferation [226]. Both in vitro and in vivo studies
indicated that murine MSCs lacking iNOS showed reduced
inhibition capability [160]. Interestingly, NO high concen-
trations may suppress immune modulation and result in
immune cell apoptosis through inhibiting signal transducer
in T cells and signal transducer and activator of transcrip-
tion 5 (STAT5) phosphorylation [226, 227]. Nevertheless,
NO is an extremely unstable oxidative molecule, and both
chemokines and adhesion molecules can contribute to it in
exerting immunosuppressive action [211, 228].
Fig. 2 Biological function of MSCs in soluble factor secreted
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IL-10
IL-10 has been reported to play a significant part in
MSC-regulated immunosuppression [134]. Antigen-
presenting cells such as dendritic cells and monocytes
could work with MSCs to induce IL-10 secretion [229].
Furthermore, by stimulating E prostanoid receptors,
macrophages can deliver large quantities of IL-10, thereby
protecting tissues against neutrophils migration [230].
CC-chemokine ligand 2 (CCL2)
As a metalloproteinase-processed chemokine, CC-
chemokine ligand 2 (CCL2) antagonizes the function of
CC-chemokine receptor 2 (CCR2), being the cognate
receptor of CCL2 [231]. Binding of CCL2 to CCR2 has
been demonstrated to mediate immunosuppression of
MSCs through inhibiting migration and activation effects
on TH17 cells in experimental autoimmune encephalo-
myelitis (EAE) [232]. Moreover, CCL2 secreted by mouse
MSCs facilitate monocyte migration from the bone
marrow into the blood stream, confirming the point that
interaction of MSC with innate immune responses
influences the immune system [232].
Prostaglandin E2 (PGE2)
Another immunosuppressive factor secreted by inflamma-
tory stimulus-induced MSCs is PGE2, regulating immuno-
suppression of MSCs in macrophages, DCs, T cells, and
NK cells [217, 219]. In vitro, PGE2 produced by mouse
MSCs restrain some cell functions like TNF migration
and generation [233]. In addition, IL-10-dependent PGE2,
in an experimental mouse model of sepsis, has been indi-
cated to play a crucial role in effectively treating mice with
MSCs [217]. More importantly, PGE2 cooperates with
IDO and exerts immunosuppressive actions in human
MSCs like inhibiting NK cell cytolytic activity and T cell
proliferation [219]. It seems that depending on the inflam-
matory microenvironment, all these molecules exert their
functions. Thus, future research should focus on mediator
mechanisms regulating the immunosuppressive charac-
teristics of MSCs and their local microenvironments,
providing a wide perspective for therapeutic application
of MSCs [218].
An outlook on the future
The aim of skin regeneration is to achieve structural and
functional reconstruction, reduce scar formation, and
improve the quality of wound healing. Stem cell-based
therapy has offered a novel and powerful strategy in
burns and wound management. Stem cells have been
demonstrated to have considerable potential in skin
tissue regeneration, as these cells can not only regenerate
lost tissue but also promote wound repair through a para-
crine manner. Several cell types such as embryonic stem
cells, iPSCs, and mesenchymal stem cells are currently
under intense investigation [111]. The availability of adult
stem cells and iPS cells in the patient provides opportu-
nities for generating these structures without the risk of
immune rejection [7]. Although advances in the field of
hiPSCs have grown exponentially, much still needs to be
understood and improved upon in terms of the re-
programming process itself, the differentiation potential of
cells, the difference between iPSCs and ESCs, “dark side”
to induced pluripotency, and their future use in clinical
therapy [234, 235]. Recent data on the MSC therapy in
cutaneous repair have showed several reasons why mesen-
chymal stem cells provide unique and effective support
for stimulating the wound-healing process in a chronic
wound. Ultimately, these cells have the ability to suppress
excessive inflammation and reduce scarring while stimu-
lating de novo angiogenesis in the wound bed, all leading
to promising outcomes in chronic wound repair [236].
Despite the rapid progress in evaluating the efficacy of
MSC transplantation for wound healing, several questions
still need to be addressed. Further studies are necessary to
characterize the niche of MSC, which helps MSCs to be
effective in the wound-healing process. Further investi-
gation of the experimental and clinical application of stem
cells in wound healing is necessary to identify the ideal
source of stem cells and the most efficacious mode of cell
delivery [111]. The use of stem cells has been partially
effective; however, the potential risks of malignant tera-
toma formation and long-term adverse effects of the stem
cells should be considered, and more extensive studies are
required in this regard [237]. In addition, there is a lack of
information on long-term outcomes of skin wound treat-
ment using such regenerative therapies. Nevertheless, for
all the aforementioned reasons, researchers should be
encouraged to increase the knowledge of cell-based
regenerative therapies, and future studies should focus on
developing a solid therapy for the treatment of skin
wounds in mammals [59]. We maintain that these prob-
lems will certainly be resolved by developments in cell
biology, tissue engineering, and regenerative medicine.
Conclusion
Wound healing has always been the most challenging
issue owing to the presence of various cell and mole-
cules working in an orchestrating way. Any disorder can
cause healing failure and result in progression of an
acute wound to a chronic wound. Thus far, various
procedures have been employed in the treatment of skin
ulcers among which cell-based therapy particularly adult
stem cell has emerged as a promising treatment to
promote scarless wound healing. Through the capability
of mesenchymal stem cells in immunomodulation and
tissue regeneration, they have received particular atten-
tion to other adult stem cells. Clinical data demonstrated
that autologous MSC transplantation promoted healing
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in all wound repair phases. However, harvesting and
isolating an optimized pool of MSC with high purity
obstructs the progress of developing new therapies. Thus,
the characterization of MSCs with niche-specific factors
still remains a challenge for researchers. To overcome
these limitations, understanding of cellular and molecular
mechanisms underlying stem cell action is necessary.
Subsequently, improvement methods of stem cell delivery
and identification of the ideal source are needed for
clinical application of these cells in wound healing.
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